NCT02314377

Bevacizumab Therapy for Brain Arteriovenous Malformation

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.

Detailed description

Brain AVMs are relatively rare, though their potential for ICH along with the existence of effective treatments makes their diagnosis and management essential to the community. The 2-4% annual incidence of such secondary ICH creates controversy regarding treatment for asymptomatic patients. Brain AVMs thus require multidisciplinary evaluation for optimal management especially for surgical grades III - V lesions that often require some combination of embolization, microsurgery, and/or radiosurgical treatment. Currently there is no designated medical therapy for bAVM, though there is growing animal and human evidence supporting a role for bevacizumab to reduce the size of AVMs in the brain and liver, respectively. This proposal is a pilot study to assess the efficacy and safety of bevacizumab in humans with bAVMs.

Conditions

• Brain Arteriovenous Malformation

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).

Timeline

• Start date: 2016-06-01
• Primary completion: 2018-12-01
• Completion: 2019-12-01
• First posted: 2014-12-11
• Last updated: 2020-03-03

Locations

1 site across 1 country: United States